The world’s #1 lab management platform. Streamline communication, consolidate ordering, and track inventory.\n\nGiven the high speed of innovation, it's no surprise that the tools used to manage lab research haven't kept pace. Spreadsheets, email and sticky notes just aren't enough. They actually hold back research as they waste valuable time and money.\n\nQuartzy is changing all of that. Our breakthrough platform helps life scientists and lab managers handle, order and optimize their resources every day.\n\nThe New York Stem Cell Foundation uses Quartzy as it hunts for cures for diabetes and ALS. Impossible Foods uses Quartzy as it invents new plant-based proteins. More than 28,000 other startups, nonprofits, multi-nationals and leading academic labs now use Quartzy; we're well on our way to becoming the global standard for lab management.\n\nYet our journey has just begun. We need your help. Come join us as we build a product, a company and an enduring culture that can speed the pace of scientific discovery and make a true impact in the world.

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/